Evidence map›Paper›PMID 31513782›Full record

ArticleExperimental cell research2019

Establishment of ornithine transcarbamylase deficiency-derived primary human hepatocyte with hepatic functions.

Shan Su, Cristina Di Poto, Alexander H Kroemer, Wanxing Cui, Rabindra Roy, Xuefeng Liu, Habtom W Ressom

Open access · greenAbstract read
In one paragraph

Article in Experimental cell research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Conditional Cell Reprogramming in Modeling Digestive System Diseases.Frontiers in cell and developmental biology · 2021
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Shan SuLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Cristina Di PotoLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Alexander H KroemerMedStar Georgetown University Hospital, Washington, DC, USA.
Wanxing CuiMedStar Georgetown University Hospital, Washington, DC, USA.
Rabindra RoyLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Xuefeng LiuDepartment of Pathology, Georgetown University Medical Center, Washington, DC, USA.
Habtom W RessomLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. Electronic address: hwr@georgetown.edu.
Georgetown University · USGeorgetown University Medical Center · USMedStar Georgetown University Hospital · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Analysis of Racial Disparities in HCC by Systems MetabolomicsU01CA185188 · NCI · GEORGETOWN UNIVERSITY · PI RESSOM, HABTOM W · 2015 to 2019
$1.7M
Systems Metabolomics for HCC Biomarker DiscoveryR01GM123766 · NIGMS · GEORGETOWN UNIVERSITY · PI RESSOM, HABTOM W · 2017 to 2021
$1.5M
NCI NIH HHS P30 CA051008NCI NIH HHS U01 CA185188NIGMS NIH HHS R01 GM123766
6 · The paper itself

Abstract

A long-term hepatocyte culture maintaining liver-specific functions is very essential for both basic research and the development of bioartificial liver devices in clinical application. However, primary hepatocytes rapidly lose their proliferation and hepatic functions over a few days in culture. This work is to establish an ornithine transcarbamylase deficiency (OTCD) patient-derived primary human hepatocyte (OTCD-PHH) culture with hepatic functions for providing an in vitro cell model. Liver tissue from an infant with OTCD was dispersed into single cells. The cells were cultured using conditional reprogramming. To characterize the cells, we assessed activities and mRNA expression of CYP3A4, 1A1, 2C9, as well as albumin and urea secretion. We found that the OTCD-PHH can be subpassaged for more than 15 passages. The cells do not express mRNA of fibroblast-specific maker, whereas they highly express markers of epithelial cells and hepatocytes. In addition, the OTCD-PHH retain native CYP3A4, 1A1, 2C9 activities and albumin secretion function at early passages. The OTCD-PHH at passages 2, 6, 9 and 13 have identical DNA fingerprint as the original tissue. Furthermore, under 3D culture environment, low urea production and hepatocyte marker staining of the OTCD-PHH were detected. The established OTCD-PHH maintain liver-specific functions at early passages and can be long-term cultured in vitro. We believe the established long-term OTCD-PHH culture is highly relevant to study liver diseases, particularly in infants with OTCD.

Indexed as

3T3 CellsAnimalsCell LineCell Line, TumorCytochrome P-450 CYP1A1Cytochrome P-450 CYP3AEpithelial CellsHepatocytesHep G2 CellsHumansInfantLiverLiver DiseasesMaleMiceOrnithine Carbamoyltransferase Deficiency DiseaseCytochrome P-450 CYP1A1Cytochrome P-450 CYP3ARNA, MessengerCYP450 activityLong-term cultureOrnithine transcarbamylase deficiency (OTCD)Primary human hepatocyte (PHH)

Identifiers

PMID31513782
PMCPMC6786762
OpenAlexW2972318734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.